Expression profile of standard and variants forms of CD44 related to prostate cancer behavior

International Journal of Biological Markers

Volumn 30, Issue 1, 2015, Pages e49-e55

  Moura, Caio M ^a   Pontes, Jose ^a   Reis, Sabrina T ^a   Viana, Nayara I ^a   Morais, Denis R ^a   Dip, Nelson ^a   Katz, Betina ^a   Srougi, Miguel ^a   Leite, Katia R M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CD44; Isoforms; Prostate cancer

Indexed keywords

HERMES ANTIGEN; CD44 PROTEIN, HUMAN; ISOPROTEIN;

ADULT; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER GROWTH; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; SURVIVAL RATE; AGED; DISEASE FREE SURVIVAL; GENETICS; MALE; METABOLISM; PATHOLOGY; PREVENTION AND CONTROL; PROSTATIC NEOPLASMS; TUMOR RECURRENCE;

AGED; ANTIGENS, CD44; DISEASE-FREE SURVIVAL; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS;

EID: 84930068448     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000091     Document Type: Article

References (22)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1): 11-30.
2. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992; 267(16): 2215-2220.
3. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994; 151(5): 1283-1290.
4. Misra S, Heldin P, Hascall VC, et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J. 2011; 278(9): 1429-1443.
5. Zöller M. CD44:can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011; 11(4): 254-267.
6. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci. 2002; 39(6): 527-579.
7. Borland G, Ross JA, Guy K. Forms and functions of CD44. Immunology. 1998; 93(2): 139-148.
8. Krishnamachary B, Penet MF, Nimmagadda S, et al. Hypoxia regulates CD44 and its variant isoforms through HIF-1α in triple negative breast cancer. PLoS ONE. 2012; 7(8): e44078.
9. Omran OM, Ata HS. CD44s and CD44v6 in diagnosis and prognosis of human bladder cancer. Ultrastruct Pathol. 2012; 36(3): 145-152.
10. Al-Maghrabi J, Gomaa W, Buhmeida A, Al-Qahtani M, Al Ahwal M. Decreased immunoexpression of standard form of CD44 is an independent favourable predictor of nodal metastasis in colorectal carcinoma. Anticancer Res. 2012; 32(8): 3455-3461.
11. Iczkowski KA, Bai S, Pantazis CG. Prostate cancer overexpresses CD44 variants 7-9 at the messenger RNA and protein level. Anticancer Res. 2003; 23(4): 3129-3140.
12. Iczkowski KA. Cell adhesion molecule CD44: its functional roles in prostate cancer. Am J Transl Res. 2010; 3(1): 1-7.
13. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer. 2010; 46(7): 1271-1277.
14. Verkaik NS, van Steenbrugge GJ, van Weerden WM, Bussemakers MJ, van der Kwast TH. Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. Lab Invest. 2000; 80(8): 1291-1298.
15. Kito H, Suzuki H, Ichikawa T, et al. Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate. 2001; 49(2): 110-115.
16. Lou W, Krill D, Dhir R, et al. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res. 1999; 59(10): 2329-2331.
17. Yang K, Handorean AM, Iczkowski KA. MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro. Int J Clin Exp Pathol. 2009; 2(4): 361-369.
18. Ghatak S, Hascall VC, Markwald RR, Misra S. Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor. J Biol Chem. 2010; 285(26): 19821-19832.
19. Robbins EW, Travanty EA, Yang K, Iczkowski KA. MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells. BMC Cancer. 2008; 8(1): 260.
20. Omara-Opyene AL, Qiu J, Shah GV, et al. Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. Lab Invest. 2004; 7: 894-907.
21. Tei H, Miyake H, Harada KI, Fujisawa M. Expression profile of CD44s, CD44v6, and CD44v10 in localized prostate cancer: Effect on prognostic outcomes following radical prostatectomy. Urol Oncol. 2014; 13: 1078.
22. Gotoda T, Matsumura Y, Kondo H, et al. Expression of CD44 variants and prognosis in oesophageal squamous cell carcinoma. Gut. 2000; 46(1): 14-19.